NJ-OPEX
11.3.2024 15:01:27 CET | Business Wire | Press release
OPEX® Corporation, a global leader in Next Generation Automation for almost 50 years, today announced the launch of its newest automated sorting and order retrieval solutions―OPEX Sure Sort® X with OPEX Xtract™. These innovative technologies were officially unveiled by company leadership at MODEX 2024, the largest manufacturing and supply chain trade event, held this year at the Georgia World Congress Center in Atlanta.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311187962/en/
OPEX® Sure Sort® X with OPEX Xtract™ (Photo: Business Wire)
OPEX Sure Sort X represents the next generation of high-speed, automated sorting. It is the most robust industrial sorting solution available in the market, unmatched in terms of its compact footprint, performance rates, and cost-effectiveness. This universal system can handle nearly 100% of customer-sortable items weighing up to 20 pounds (9 kg), and sort items into a configurable array of mixed bin sizes and types.
When Sure Sort X is paired with Xtract―OPEX’s revolutionary new automated order retrieval system―the task of retrieving totes and transferring their contents into shipping containers is now fully automated, as well. The result is a one-touch solution that can eliminate the need to manually sort and transfer boxes downstream.
"OPEX remains dedicated to innovations that align with the evolving demands of the market," stated Alex Stevens, President of Warehouse Automation at OPEX. "We have received feedback from our customers that they want one integrated solution to sort, retrieve, and automatically get the product into its final container. Our new solutions, Sure Sort X and Xtract, are a response to those requests. This cutting-edge technology is designed to automate multiple manual tasks with a simple, one-touch solution.”
Developed based on feedback from the international business community, Sure Sort X applies OPEX Corporation’s innovative, industry-leading Sure Sort technology, introduced in 2017. With its enhanced product handling capabilities, Sure Sort X is the single most versatile and configurable sorting solution available. It can handle items 60 percent smaller, nearly 20 percent larger, and up to 300 percent heavier than its predecessor, all while maintaining a consistent throughput of up to 2,100 items per hour.
The system’s iBOT® delivery vehicles utilize sophisticated motion algorithms that allow them to maneuver throughout the system efficiently, with the ability to change destination in real time while in transit. These iBOTs can drive in and out of the system while Sure Sort X continues to run, ensuring the highest level of uptime and availability. In addition, Sure Sort X can operate in both chilled and ambient environments. Installation can occur in as little as one week.
OPEX Xtract can be added to any Sure Sort X system by introducing retrieval iBOTs to work in conjunction with the traditional sortation iBOTs found in Sure Sort X. Xtract iBOTs move in a loop that has both horizontal and vertical segments within the Sure Sort X aisle, and can handle up to 200 extracted totes per hour. All of the iBOTs are self-charging and can easily be added to or removed from the system.
The system can retrieve standard totes or can be outfitted with Xtract totes, which are uniquely designed to transport items from the sort location to any available roller, v-chute, transfer (RVT) module. If these totes are used, once all products for a relevant order have been deposited into the Xtract totes, each tote is retrieved and transported to the RVT module, where the tote door opens and releases the items into the final shipping box or order container.
Soon after its unveiling in the US at MODEX, Sure Sort X will make its European debut at the LogiMAT expo in Stuttgart, Germany, on March 19, 2024, at the OPEX exhibit in Hall 7, Stand 7D53.
Sure Sort X and Xtract join the existing Warehouse Automation portfolio at OPEX, which includes Sure Sort®—the industry-leading, high-speed, small-item robotic sorting system; Perfect Pick®, a robotic goods-to-person picking solution that dramatically improves speed, efficiency, and reliability, and Infinity®―the most advanced goods-to-person solution available in warehouse automation. All are custom configured for each client and designed to completely transform supply chain infrastructure.
For nearly five decades, OPEX Corporation has served as a trusted partner, collaborating closely with clients to develop customized, scalable solutions that transform how business is conducted. OPEX continuously reimagines automation technology to help clients solve their most significant business challenges, today and in the future.
About OPEX
OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,600 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311187962/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
